eli lilly glp 1 drugs FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and Lilly's Trulicity joins pay-for-performance trend
Description
Diabetologia (2010) 53(1):1539
S.de PaivaI
Interestingly, the rise in hormone-sensitive lipase (HSL) phosphorylation within cardiac myocytes appears to rely on a GIPR-mediated increase in ERK phosphorylation
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Your care plan will be personalized to fit your unique metabolic needs and health goals
Plos One
